Beacon Therapeutics, a private ophthalmic gene therapy company, featured this week for its expanding scientific footprint and ongoing work in inherited retinal diseases. The company is deepening its presence at major industry forums while advancing clinical programs in X-linked retinitis pigmentosa and geographic atrophy.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beacon plans to participate in the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston, running from May 11–15. Chief Medical Officer Daniel C. Chung and Principal Scientist Bruno Doreste are slated to present scientific posters highlighting the firm’s gene therapy and ophthalmology research.
The ASGCT presence underscores Beacon’s engagement with the broader gene therapy community and its focus on X-linked retinitis pigmentosa, as reflected in conference communications. While no new clinical or regulatory data were disclosed, the company is clearly using the event to showcase its science and build relationships with peers and potential partners.
These activities follow a recent week in which Beacon reported 12-month Phase 2 DAWN data for its lead candidate laru-zova in X-linked retinitis pigmentosa and outlined pivotal trial timelines. Taken together, the stepped-up conference visibility and prior mid-stage results support Beacon’s positioning in retinal gene therapy and may help underpin future collaborations and financing.